|Bid||0.0000 x 1400|
|Ask||0.0000 x 4000|
|Day's range||3.6700 - 3.9000|
|52-week range||3.6660 - 13.5200|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||16.40|
NEW YORK, January 12, 2022--PAVmed and Lucid Diagnostics welcome new full-time investor relations team.
NEW YORK, January 06, 2022--Lucid Diagnostics to participate in a Fireside Chat at the 24th Annual Needham Virtual Growth Conference.
NEW YORK, December 01, 2021--PAVmed subsidiary Lucid Diagnostics launches EsoGuard telemedicine program in partnership with UpScriptHealth.